K1 Opening & Keynote Lecture I (plenary) Wednesday, 24 August 2016 13:00-13:45
|
|
|
Welcome addresses
|
15 min |
|
25th Anniversary of the European Congresses on Alternatives to Animal Testing in Linz, Austria Horst Spielmann, DE-Berlin |
30 min |
|
The 3Rs in relation to REACH Derek Knight, FI-Helsinki |
K2 Keynote Lecture II (plenary) Thursday, 25 August 2016 09:00-09:30
|
30 min |
|
Real world medicine and real world patients: Something that animal testing can never approximate Michael Liebmann, US-Kennett Square |
K3 Keynote Lecture III (plenary) Friday, 26 August 2016 09:00-09:30
|
30 min |
|
Combating infectious diseases, novel approaches and in vitro models Claus-Michael Lehr, DE-Saarbruecken |
K4 Keynote Lecture IV (plenary) Saturday, 27 August 2016 09:00-09:30
|
30 min |
|
The CRISPR/Cas9 sytstem: a game changer in the life sciences Malte Spielmann, DE-Berlin |
1 EU 3Rs Projects in Toxicology & other 3Rs Funding Institutions Wednesday, 24 August 2016 13:50-15:20
|
30 min |
|
SEURAT-1: A cluster of European projects that have changed the landscape for 21st century European toxicology Andrea-Nicole Richarz, IT-Ispra |
30 min |
|
The EU-ToxRisk project: A European flagship program for mechanism-based safety sciences and risk assessment Mardas Daneshian, DE-Konstanz |
15 min |
|
The Lush Prize - an overview Rebecca Ram, UK-Manchester |
15 min |
|
A retrospective on 40 years of funding animalfree methods Stefanie Schindler, CH-Bern |
2 Global Cooperation on Implementing the 3Rs Wednesday, 24 August 2016 15:50-17:20
|
20 min |
|
The current status of non-animal test methods and prospects for Asian cooperation Hajime Kojima, JP-Tokyo |
20 min |
|
The current status of nonanimal alternatives in the life sciences in China Mao Ling Wei, CN-Chengdu |
20 min |
|
Examination of the gap between validation and (real) regulatory acceptance Erin Hill, US-Gaithersburg |
15 min |
|
Norecopa: providing global 3R-resources for animal research Adrian Smith, NO-Oslo |
15 min |
|
MAD world? Promoting the greater mutual acceptance of data Jarlath Hynes, BE-Brussels |
paid advertising
|
3 Ethical and Legal Issues Thursday, 25 August 2016 14:00-15:30
|
15 min |
|
An ethical challenge to the normalisation of animal experimentation Kay Peggs, UK-Winchester |
15 min |
|
A proposal for a catalogue of criteria to objectify the harm-benefit analysis of proposed projects including animal experiments Norbert Alzmann, DR-Tuebingen |
15 min |
|
Applying the harm benefit assessment under the EU Directive – what does it mean in practice for animals? Katy Taylor, UK-London |
15 min |
|
Biotechnological chimeras and experimentation: legislative lacunae legerdemain? Maureen O'Sullivan, IR-Galway |
15 min |
|
Ethical aspects of the Crispr/Cas9 technology Henriette Bout, NL-Amsterdam |
15 min |
|
Non-human primates in neuroscience research: Can it be ethical, if it isn’t scientifically necessary? Jarrod Bailey, UK-London |
4 Implementing Dir 2010/63/EU Thursday, 25 August 2016 09:35-11:10
|
20 min |
|
The role of the National Committees (NC) and Animal Welfare Bodies (AWB) under Directive 2010/63/EU Susanna Louhimies, BE-Brussels |
15 min |
|
Towards a harmonized approach: Role of the German National Committee for the Protection of Animals Used for Scientific Purposes in the process of implementation of the Directive 2010/63/EU Justyna Chmielewska, DE-Berlin |
15 min |
|
Role of the Swedish national committee in the harmonization of project authorization and evaluation Katarina Cvek, SE-Uppsala |
15 min |
|
Establishing a culture of care by implementing AUGUST – a new and strong initiative at Aarhus University Birgitte Kousholt, DK-Aarhus N |
15 min |
|
From the guideline to the bench – The role of science based policy advice in implementing EU Dir 63/2010 in Germany Henning Steinicke, DE-Halle |
15 min |
|
Animal welfare requirements – significant room for improvement Irmela Ruhdel, DE-Neubiberg |
5.1 Novel Approaches in Efficacy and Safety Testing – 3D models I Thursday, 25 August 2016 09:35-11:05
|
20 min |
|
A three-dimensional bioprinted liver equivalent for human-on-a-chip toxicity screenings Tobias Grix, DE-Berlin |
20 min |
|
Studying liver toxicity and disease modelling using bioprinted 3D human liver tissue Christine Daly, UK-London |
20 min |
|
Hepatic differentiation of hiPSC in co-culture with endothelial cells using different culture media Nora Freyer, DE-Berlin |
15 min |
|
In vitro study of melatonin effect on HepG2 cells treated with IL-6 in newly developed liver on chip device Mi Jang, DE-Saarbruecken |
15 min |
|
A modular cell sheet-based approach towards 3D tissue models Marie Weinhart, DE-Berlin |
5.2 Novel Approaches in Efficacy and Safety Testing – 3D models II Thursday, 25 August 2016 11:30-13:00
|
25 min |
|
OncoCilAir™: Organotypic human in vitro model for lung cancer research Samuel Constant, CH-Plan-les-Ouates |
20 min |
|
Migrating to the 3rd dimension: the “Neurosphere Assay” to study migration disturbances during neurodevelopment Marta Barenys, DE-Duesseldorf |
20 min |
|
The 'Neurosphere Assay' as a valuable part of a DNT testing strategy Ellen Fritsche, DE-Duesseldorf |
20 min |
|
ATERA: advanced 3D human tissue models and exclusive testing services for cosmetic, consumer product and pharmaceutical industry Bart De Wever, LU-Esch-sur-Alzette |
5.3 Novel Approaches in Efficacy and Safety Testing – Multi-Organ-Chips I Friday, 26 August 2016 09:35-11:05
|
20 min |
|
From organoid technology to Multi-Organ-Chip development for substance testing Mark Rosowski, DE-Berlin |
20 min |
|
Increasing biological relevance in vitro: From single microtissues to micro-physiological systems Jens Kelm, CH-Zurich |
20 min |
|
Creating organotypic oxygen tension in cell culture chambers using perfused flow and flexible chamber geometry Kelly Davidge, UK-Rotherham |
15 min |
|
Online TEER measurements in Homunculus system for orally administered drugs testing Dmitry Sakharov, RU-Moscow |
15 min |
|
Utilization of Hommunculus platform for evaluation of cytochrome P450 activity in "liver-on-a-chip" Andrey Poloznikov, RU-Moscow |
5.4 Novel Approaches in Efficacy and Safety Testing – Multi-Organ-Chips II Friday, 26 August 2016 11:30-13:00
|
20 min |
|
Bringing a human heart & fat on a chip: microphysiological platforms as in vitro models of cardiac and adipose tissue Peter Loskill, DE-Stuttgart |
20 min |
|
High-throughput microfluidic platform for culture of 3D-kidney tissue models Henriëtte Lanz, NL-Leiden |
20 min |
|
Towards lung disease-on-chip models and personalized medicine application Colette Bichsel, CH-Bern |
15 min |
|
Vascularization of Multi-Organ-Chips for tissue engineering and regenerative medicine Severin Mühleder, AT-Vienna |
15 min |
|
Opportunities for Organ-on-a-Chip models in toxicological risk assessment Minne Heringa, NL-Bilthoven |
paid advertising
|
6.1 Stem Cells & Reproductive Toxicity (including mEST & hEST) - Stem Cells Thursday, 25 August 2016 11:30-13:00
|
20 min |
|
Cardiotoxicity gene and miRNA biomarkers induced by anticancer drugs Agapios Sachinidis, DE-Cologne |
20 min |
|
Practical application of human iPS cells for chemical toxicity assessment Yasunari Kanda, JP-Tokyo |
20 min |
|
A hiPSC-based test platform (DropTech®) for toxicity assessment of small molecule compounds in early stage drug discovery Ole Pless, DE-Hamburg |
15 min |
|
Replacing animal testing by genotoxicity and carcinogenic cell transformation assessment using a tissue regenerating cell line from fish with GFP-labelled histones Petra Stahlschmidt-Allner, DE-Aarbergen |
15 min |
|
A stem cell based metabolic activation system – Potential for replacing rat liver S9 fraction Cristiano F. Lerche, DE-Aarbergen |
6.2 Stem Cells & Reproductive Toxicity (including mEST & hEST) - EST Friday, 26 August 2016 14:00-15:30
|
20 min |
|
Hand1-Luc Embryonic stem cell test (Hand1-Luc EST): A reporter gene assay using engineered mouse ES cells to evaluate embryotoxicity in vitro Florian Le Coz, JP-Osaka |
20 min |
|
Automation-compatible EST assay Simon Ströbel, CH-Schlieren |
20 min |
|
Prediction of relative developmental toxicity of antifungal compounds using the ES-D3 cell differentiation assay, combined with the BeWo transport model Hequn Li, UK-Sharnbrook |
15 min |
|
Tests for the safety evaluation of a Chinese herbal medicine formula used in the treatment of atopic dermatitis Lucia Lu Li, CN-Hangzhou |
15 min |
|
Good Cell Culture Practice for stem cells, stem-cell-derived models and organ-on-chip models Mardas Daneshian, DE-Konstanz |
7.1 Refinement & Welfare: Culture of Care & Best Practice Approaches Thursday, 25 August 2016 14:00-15:30
|
15 min |
|
Implementation of 3Rs for livestock animals in bioscientific research-rationale and objectives of the newly established expert working group – LaNiV Fabienne Ferrara, DE-Berlin |
15 min |
|
Group housing of rats and rabbits - Thinking out of the box Kerstin Kleinschmidt-Dörr, DE-Darmstadt |
15 min |
|
Refinement and reduction strategies in experimental stroke Christa Thöne-Reineke, DE-Berlin
|
15 min |
|
The drinking water as application route for pain management in bone-linked mice models – Combining a refinement and a basic research study Annemarie Lang, DE-Berlin |
15 min |
|
Assessing laboratory mouse welfare using animal-based measures Elin Spangenberg, SE-Uppsala |
15 min |
|
Reducing animal numbers by half: A hybrid preparation technique for the simultaneous investigation of histology and broncho-alveolar lavage parameters of the rat lung Martin Wiemann, DE-Muenster |
7.2 Refinement & Welfare: Avoidance of Severe Suffering Friday, 26 August 2016 11:30-13:00
|
20 min |
|
Focus on severe suffering: an update on RSPCA activity to end severe suffering Elliot Lilley, UK-Horsham |
20 min |
|
Systematic reviews of animal studies equal the implementation of the 3Rs Merel Ritskes-Hoitinga, NL-Nijmegen |
20 min |
|
A proposal for a table to support the classification of the overall severity of a proposed project including animal experiments Norbert Alzmann, DE-Tuebingen |
15 min |
|
How to determine severity degrees for genetically altered rodents? Anne Zintsch, DE-Berlin |
15 min |
|
Repeated isoflurane anesthesia in female mice–Assessing the severity of stress Katharina Hohlbaum, DE-Berlin |
paid advertising
|
8.1 Replacement of Animals in Research & Use of Non-Animal Methods and Technologies - NEW Non-Animal Methods Wednesday, 24 August 2016 13:50-15:20
|
15 min |
|
Replacement and Non-Animal Methods: The importance to be the change Candida Nastrucci, IT-Rome |
15 min |
|
The process of isolation and characterisation of HUIEC - Human Intestinal Epithelial Cell Line Lidija Gradišnik, SL-Slovenia |
15 min |
|
Intestinal organoids: Functional studies on nutrient and drug transport, hormone secretion and intracellular signaling Tamara Zietek, DE-Munich |
15 min |
|
Replacement of goat xenobiotic metabolism studies beyond OCED 503 by use of rumen simulation technique (RUSITEC) Barbara Birk, DE-Ludwigshafen |
15 min |
|
Impact of New Technologies on Malignant Tumor Management and Therapy Lukas Kenner, AT-Vienna
|
15 min |
|
Three Rs in endocrine disruptor assessment – Refining sampling, reducing numbers of tested animals and replacing in vivo testing Reinhard Möller, DE-Aarbergen |
8.2 Replacement of Animals in Research & Use of non-Animal Methods and Technologies - Serum Free Media Friday, 26 August 2016 09:35-11:05
|
20 min |
|
Serum-free media and serum alternatives Jan van der Valk, NL-Utrecht |
20 min |
|
Towards the replacement of fetal bovine serum in cell culture applications Christopher Fassbender, UK-London |
20 min |
|
A fetal bovine serum free cytotoxicity test following ISO 10993-5 Joachim Wiest, DE-Munich |
15 min |
|
IONOSENSE POC: Integration of OECTs with live cells an a 12-well plate for in vitro diagnostics, Aimie Pavia, FR-Gardanne |
9.1 Predictive Toxicology - QSAR & Testing Strategies Thursday, 25 August 2016 09:35-11:05
|
20 min |
|
OECD projects on Integrated Approaches to Testing and Assessment (IATA): a combination of mechanistic information and alternative methods to improve predictive toxicology Magdalini Sachana, FR-Paris |
20 min |
|
EuroMix: using (Q)SARs, TTC, molecular docking simulation and read across as a first tier in mixture toxicity risk assessment Emiel Rorije, NL-Bilthoven |
20 min |
|
A decision-making framework for the grouping and testing Josje Arts, NL-Arnhem |
15 min |
|
A High Accuracy QSAR based on rabbit data to predict the human skin and eye irritation potential of individual constituents and mixtures Faizan Sahigara, FR-L’Isle D’Abeau |
15 min |
|
Computational profiling as a proxy for drug hazard prediction in pharmaceutical research Friedemann Schmidt, DE-Frankfurt |
9.2 Predictive Toxicology - Read Across Friday, 26 August 2016 16:00-17:30
|
20 min |
|
The use of metabolomics in vivo as read across tool: a case study with phenoxy carboxylic acid herbicides Hennicke Kamp, DE-Ludwigshafen |
20 min |
|
Supporting evidence in read across approaches: potential and limitations of new approaches and methodologies Eric Stilgenbauer, FI-Helsinki |
20 min |
|
Improving confidence in read across: A case study for the oral repeated dose toxicity of β-Olefinic alcohols Mark Cronin, UK-Liverpool |
15 min |
|
Simulating chemical kinetics and dynamics for the prediction of toxicity Alicia Paini, IT-Ispra |
15 min |
|
New possibilities in mathematical toxicology Marko Raseta, UK-York |
paid advertising
|
10.1 Toxicology I - Systemic Toxicity & Environmental Toxicity Wednesday, 24 August 2016 13:50-15:20
|
20 min |
|
EPAA contributions in the area of ADME and carcinogenicity testing Renate Weissenhorn, BE-Brussels |
20 min |
|
Exposure-Based Chemical Safety Assessment Workflow Integrating Alternative Methods: An Ab Initio Case Study for Repeated-Dose Toxicity Andrea-Nicole Richarz, IT-Ispra |
20 min |
|
Perspectives to use the fish embryo test for applications beyond acute toxicity prediction – chronic fish toxicity, endocrine disruption and developmental toxicity Stefan Scholz, DE-Leipzig |
15 min |
|
Human or mouse fibroblasts for assessing acute toxicity? Tuula Heinonen, FI-Tampere |
15 min |
|
A medium-throughput method for the analysis of (combinatorial) endocrine effects using the nematode C. elegans Silvia Vogl, DE-Berlin |
10.2 Toxicology I - Inhalation Toxicity Friday, 26 August 2016 14:00-15:30
|
15 min |
|
Evaluation of reconstituted human bronchial epithelium (MucilAir™) suitability for repeated dose testing Samuel Constant, CH-Plan-les-Ouates |
15 min |
|
Metaplastic phenotype in human primary bronchiolar epithelial cells after repeated exposure to mainstream cigarette smoke at the air-liquid interface Michaela Aufderheide, DE-Hannover |
15 min |
|
Establishment and charakterization of a lung/liver organ-on-a-chip model. Phase 1: Model charakterization David Bovard, CH-Neuchâtel |
15 min |
|
Development of an in vitro inhalation toxicity test with potential regulatory applicability Anna Maione, US-Ashland MA |
15 min |
|
Collaborative industry efforts to optimize and standardize in vitro methods suitable for tobacco regulatory science Erin Hill, US-Gaithersburg MD |
15 min |
|
Novel Aerosol exposure devices for in-vitro toxicity testing at the air/liquid interface Tobias Krebs, DE-Waldkirch |
11.1 Toxicology II - Skin Sensitization, Phototoxicity Friday, 26 August 2016 09:35-11:05
|
20 min |
|
Assessment of pre- and pro-haptens using non-animal test methods for skin sensitization Britta Wareing, DE-Ludwigshafen |
20 min |
|
Extending the limits of the hCLAT assay – test of the sensitization potential of oxidative hair dyes Karsten Mewes, DE-Duesseldorf |
20 min |
|
GARD – the future of sensitization testing using a genomics-based platform Anki Malmborg Hager, SE-Lund |
15 min |
|
ITS for skin sensitization potential – 1 out of 2 or 2 out of 3? David Roberts, UK-Liverpool |
15 min |
|
An improved reactive oxygen species assay for photosafety assessment of chemicals with limited aqueous solubility Yoshiki Seto, JP-Shizuoka |
11.2 Toxicology II - Bio-barriers & Novel Testing Concepts Friday, 26 August 2016 16:00-17:30
|
20 min |
|
Cellular and non-cellular elements of the pulmonary air-blood barrier Claus-Michael Lehr, DE-Saarbruecken |
20 min |
|
BioVaSc-TERM - a platform technology to engineer human barrier models Angela Rossi, DE-Wuerzburg |
15 min |
|
The novel ToxTracker reporter system provides mechanistic insight into the genotoxic properties of compounds and materials Giel Hendriks, NL-Leiden |
15 min |
|
Integration of conducting polymer devices with 3D human tissue models for in vitro toxicology testing Magali Ferro, FR-Gardanne |
20 min |
|
If non-animal alternative tests are accepted by regulatory agencies, will industry use them? Rodger Curren, US-Gaithersburg MD |
paid advertising
|
12 Efficacy of Drugs, Biologiocals & Vaccines Thursday, 25 August 2016 11:30-13:00
|
20 min |
|
Towards global harmonisation of 3Rs in biologicals Katrin Schutte, BE-Brussels |
20 min |
|
The “BINACLE” (binding and cleavage) assay allows in vitro determination of botulinum and tetanus neurotoxin activity Heike Behrensdorf-Nicol, DE-Langen |
20 min |
|
G-protein based ELISA as a potency test for human rabies vaccines Martine Chabaud-Riou, FR-Marcy l'Etoile |
15 min |
|
Development, optimization and validation of an in vitro skin irritation test for medical devices using the reconstructed human tissue model Epiderm Helena Kandarova, SK-Bratislava |
15 min |
|
Animal Friendly Affinity Reagents (AFAs): making animal immunisation obsolete Alison Gray, FR-Morzine |
13.1 Disease Models in vitro versus in vivo - Lung Infections Thursday, 25 August 2016 14:00-15:30
|
20 min |
|
Modeling severe infection in human lung tissue Katja Zscheppang, DE-Berlin |
20 min |
|
The use of in vitro human airway epithelia for the development of novel antivirals Samuel Constant, CH-Plan-les-Ouates |
20 min |
|
Novel cystic fibrosis in vitro model for safety and efficacy testing of new drug delivery systems against chronic Pseudomonas aeruginosa infections Jenny Juntke, DE-Saarbruecken |
15 min |
|
Transient receptor potential (TRP) ion channels activation induce increased bronchoconstriction in passive sensitized vital human ex vivo precision-cut lung slices Susann Dehmel, DE-Hannover |
15 min |
|
Modeling fungal infections within a three-dimensional perfused respiratory system Doris Wilflingseder, AT-Innsbruck |
13.2 Disease Models in vitro versus in vivo - Skin & ex vivo Tissues Wednesday, 24 August 2016 15:50-17:20
|
20 min |
|
Inflammatory skin disease models Sarah Hedtrich, DE-Berlin |
20 min |
|
An inflammatory, filaggrin-deficient skin model demonstrates hallmarks of atopic dermatitis in vitro Stefan Hönzke, DE-Berlin |
20 min |
|
Novel perspectives for in vitro models of human skin wounds Maike Windbergs, DE-Saarbrücken |
15 min |
|
Fast and label-free tracking of cell behavior in non-animal models Karin Schütze, DE-Bernried |
15 min |
|
Preclinical evaluation of CD30 as a novel molecular target in systemic mastocytosis Peter Valent, AT-Vienna |
13.3 Disease Models in vitro versus in vivo - Other Organs Friday, 26 August 2016 14:00-15:30
|
20 min |
|
A human neuronal in vitro model for application in biomedical research and in pharmacological and toxicological investigations Stefan Schildknecht, DE-Konstanz |
20 min |
|
3D in vitro tissue models for infection studies with human pathogens Matthias Schweinlin, DE-Wuerzburg |
20 min |
|
Retinal organotypic cultures as disease model for ophthalmic diseases – recently proposed models Sven Schnichels, DE-Tuebingen |
15 min |
|
Analysis of a novel ex vivo organ model to simulate neurodegeneration in retina Stephanie Joachim, DE-Bochum |
15 min |
|
Recent developments of disease and human in vitro models of the blood-brain barrier Winfried Neuhaus, AT-Vienna |
13.4 Disease Models in vitro versus in vivo - Using Data Bases & Information Tools Friday, 26 August 2016 16:00-17:30
|
25 min |
|
Defining the optimal animal model for translational research using gene set enrichment analysis Matthias Steinfath, DE-Berlin |
25 min |
|
Modernizing law and policy to support innovation in preclinical pharmaceutical testing in the United States Elizabeth Baker, US-Washington |
25 min |
|
From bedside to bench – adding human context to in vitro models Brigitte Landesmann, IT-Ispra |
14.1 3Rs in Education and Academia - Academia Wednesday, 24 August 2016 15:50-17:20
|
25 min |
|
BB3R – educating the next generation of scientists Monika Schäfer-Korting, DE-Berlin |
20 min |
|
ReThink3R – innovation strategies for young scientists – Report of the first workshop Annemarie Lang, DE-Berlin |
15 min |
|
CAAT Academy: From inception to launching Francois Busquet, BE-Ixelles |
15 min |
|
A Course in Replacement Alternatives: To give the good example Candida Nastrucci, IT-Rome |
15 min |
|
Improving transparency on quality and translatability of animal studies using new science driven approach Judith van Luijk, NL-Nijmegen |
14.2 3Rs in Education and Academia - Education Friday, 26 August 2016 11:30-13:00
|
20 min |
|
Teaching practical applications of animal welfare – a review over 10 years of the FELASA B-Course in Vienna Christiane Winding, AT-Vienna |
20 min |
|
Education and Training Platform for Laboratory Animal Science (ETPLAS) Jan van der Valk, NL-Utrecht |
20 min |
|
Development and establishment of an interdisciplinary international master program for laboratory animal science (MLAS): a contribution to the 3R principles Julia Steitz, DE-Aachen |
15 min |
|
Advanced training course for veterinarians to qualify for Animal Welfare Officer Christa Thöne-Reineke, DE-Berlin |
15 min |
|
Establishment of an education program that meets the needs of researchers and animals Jan Baumgart, DE-Mainz |
15.1 Young Scientists Lectures I Saturday, 27 August 2016 09:30-11:15 |
15 min |
|
The use of human (non- 3D equivalent) skin assays (SkimuneTM) for the detection of adverse reactions, potency and efficacy Ana Ribeiro, UK-Newcastle |
15 min |
|
An in vitro system to predict the pro-fibrotic potential of carbon nanotubes in the lung Hana Barosova, CH-Fribourg |
15 min |
|
Use of human derived liver cell lines for the detection of genotoxic carcinogens Monika Waldherr, AT-Vienna |
15 min |
|
Chronologically-aged fibroblasts significantly alter the morphology of reconstructed human skin Christian Hausmann, DE-Berlin |
15 min |
|
Three dimensional cell culture model for toxicity and efficacy tests Karolin Fröhlich, DE-Jena |
15 min |
|
Development of an innovative moving interface for an in vitro model of the epithelial intestinal barrier Joana Costa, IT-Massarosa |
15 min |
|
Label-free monitoring of HepG2 spheroids – a platform for automated liver toxicity screening Sebastian Eggert, DE-Munich
|
15.2 Young Scientists Lectures II Saturday, 27 August 2016 11:40-13:10
|
15 min |
|
Characterization of reconstructed human skin containing Langerhans cells to monitor molecular events in skin sensitization Gerrit Müller, DE-Berlin |
15 min |
|
A novel 3D in vitro model of the deep lung in both healthy and diseased state for screening of safety and efficacy of pulmonary (nano)medicines Remi Hendrix, DE-Saarbruecken |
15 min |
|
Effects of anti-tumor drugs bevacizumab and cisplatin on cancer cell invaded human ex vivo lung tissue in an organotypic model as an alternative to animal experiments Sebastian Konzok, DE-Hannover |
15 min |
|
Safety assessment in EU-substance law: An open door for alternative methods Lena Hehemann, CH-Fribourg |
15 min |
|
Litter loss as a neglected welfare problem? Charlotte S. Leidinger, DE-Mainz |
15 min |
|
Assessment of Hen’s Egg Test Chorioallantoic Membrane (HET-CAM) for screening of anticancer activities of drugs Mahmoud Galal, EG-Cairo |
R1 Round Table I - "Building a career in the 3Rs area: successful biotech SMEs" (plenary) Wednesday, 24 August 2016 17:25-18:25
|
|
|
|
R2 Round Table II - Implementing the concept of "Integrated Approaches to Testing and Assessment (IATA)" into international regulatory testing (plenary) Thursday, 25 August 2016 16:00-17:00
|
|
|
|
P1 Poster Session I Thursday, 25 August 2016 17:00-19:00
|
|
|
Survey of the posters with presence of the authors. The titles and authors of this poster session I will be published separately. All posters will be present during all days of the congress. |
|
|
|
P2 Poster Session II Friday, 26 August 2016 17:30-19:00
|
|
|
Survey of the posters with presence of the authors. The titles and authors of this poster session II will be published separately. All posters will be present during all days of the congress. |
|
|
|